Novartis MS Drug Shows Strong Safety Profile Despite Missing Efficacy Benchmarks

By Andrew Joseph · STAT News · 2026-10-23

Novartis MS Drug Shows Strong Safety Profile Despite Missing Efficacy Benchmarks

According to STAT News, Phase 3 trial data for remibrutinib revealed a significant reduction in relapse rates for patients with multiple sclerosis. While the Novartis treatment fell short of the efficacy marks set by a competing Roche therapy, it appears to avoid the severe liver

According to STAT News, Phase 3 trial data for remibrutinib revealed a significant reduction in relapse rates for patients with multiple sclerosis. While the Novartis treatment fell short of the efficacy marks set by a competing Roche therapy, it appears to avoid the severe liver